Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Revenue (2020 - 2025)

Historic Revenue for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • TScan Therapeutics' Revenue rose 13937.08% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 1002.99%. This contributed to the annual value of $2.8 million for FY2024, which is 8662.17% down from last year.
  • According to the latest figures from Q3 2025, TScan Therapeutics' Revenue is $2.5 million, which was up 13937.08% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Revenue registered a high of $7.2 million during Q4 2023, and its lowest value of $536000.0 during Q2 2024.
  • For the 5-year period, TScan Therapeutics' Revenue averaged around $2.9 million, with its median value being $2.9 million (2021).
  • Per our database at Business Quant, TScan Therapeutics' Revenue soared by 73172.41% in 2021 and then tumbled by 9077.8% in 2024.
  • Quarter analysis of 5 years shows TScan Therapeutics' Revenue stood at $2.9 million in 2021, then rose by 8.44% to $3.1 million in 2022, then skyrocketed by 132.99% to $7.2 million in 2023, then crashed by 90.78% to $665000.0 in 2024, then skyrocketed by 277.59% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $3.1 million for Q2 2025, and $2.2 million during Q1 2025.